2022
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidCOVID-19COVID-19 VaccinesFemaleHumansMaleMiddle AgedRheumatologySurveys and QuestionnairesConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regression
2021
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Izadi Z, Brenner E, Mahil S, Dand N, Yiu Z, Yates M, Ungaro R, Zhang X, Agrawal M, Colombel J, Gianfrancesco M, Hyrich K, Strangfeld A, Carmona L, Mateus E, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado A, Mazeda Pereira A, Hasseli R, Pfeil A, Lorenz H, Hoyer B, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet A, Al Emadi S, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Isnardi C, Quintana R, Soriano E, Hsu T, D’Silva K, Sparks J, Patel N, Xavier R, Marques C, Kakehasi A, Flipo R, Claudepierre P, Cantagrel A, Goupille P, Wallace Z, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Griffiths C, Barker J, Smith C, Yazdany J, Kappelman M, Bachelez H, Capon F, Coker B, De La Cruz C, Mason K, Di Meglio P, Gelfand J, Gisondi P, Iversen L, Jullien D, Lambert J, Langan S, McAteer H, Meynell F, Moorhead L, Naldi L, Puig L, Reynolds N, Spuls P, Torres T, Tsakok T, Vincent A, Warren R, Waweru H, Ng S, Gearry R, Reinisch W, Rahier J, Lewis J, Kaplan G, Steinwurz F, Kissous-Hunt M, Modesto I, Konings M, Dahou B, Gómez G, Roberts K, Baez R, Castro Coello V, Haye Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Maldonado Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Gálvez Elkin M, Medina M, Savio V, Rojas Tessel R, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Gonzalez Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Rodriguez Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Velasco Zamora J, Kisluk B, Castaños Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Machado Ribeiro F, Euzebio Ribeiro S, Pinheiro M, Ibáñez S, Chassin Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Guzman Melgar G, So H, Király M, Vojdanian M, Balbir Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta Montiel B, Castillo Ortiz A, Zamora Tehozol E, Vega Morales D, Cervántes Rosete D, Martín Nares E, Rodriguez Reyna T, Rull Gabayet M, Alpízar Rodríguez D, Irazoque F, Jimenez X, Geurts van Bon L, Zijlstra T, Hoekstra M, Al Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte Gil M, Nowakowski J, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre Rubio N, Alegre Sancho J, Corteguera Coro M, Cobeta Garcia J, Torres Martin M, Campos J, Gomez Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Ezzati F, Parks D, Karp D, Quiceno G. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open 2021, 4: e2129639. PMID: 34661663, PMCID: PMC8524310, DOI: 10.1001/jamanetworkopen.2021.29639.Peer-Reviewed Original ResearchConceptsTNF inhibitor monotherapyCOVID-19-associated hospitalizationTumor necrosis factor inhibitorsNecrosis factor inhibitorsInhibitor monotherapyInflammatory bowel diseaseTNF inhibitorsCOVID-19 outcomesPooled analysisMethotrexate monotherapyImmunomodulatory treatmentMethotrexate therapyClinical characteristicsCohort studyBowel diseaseFactor inhibitorsInflammatory diseasesMAIN OUTCOMEAdverse COVID-19 outcomesCOVID-19Multivariable logistic regression modelMultilevel multivariable logistic regression modelsJAK inhibitor monotherapyKinase inhibitor monotherapyRisk of hospitalizationAssociations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Sparks J, Wallace Z, Seet A, Gianfrancesco M, Izadi Z, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Pons-Estel G, Isnardi C, Berbotto G, Hsu T, D’Silva K, Patel N, Kearsley-Fleet L, Schäfer M, Ribeiro S, Al Emadi S, Tidblad L, Scirè C, Raffeiner B, Thomas T, Flipo R, Avouac J, Seror R, Bernardes M, Cunha M, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, de Souza V, da Mota L, Gomides A, Dieudé P, Nikiphorou E, Kronzer V, Singh N, Ugarte-Gil M, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Yazdany J, Dahou B, Quintana R, Gómez G, Roberts K, Baez R, Coello V, Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Elkin M, Medina M, Savio V, Tessel I, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Zamora J, Kisluk B, Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de Fernandez S, Argentina C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Ribeiro F, Ribeiro S, Pinheiro M, Ibáñez S, Chassin-Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Melgar G, So H, Király M, Vojdanian, Balbir-Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta-Montiel B, Castillo-Ortiz A, Zamora-Tehozol E, Vega-Morales D, Rosete D, Martín-Nares E, Rodriguez-Reyna T, Gabayet M, Alpízar-Rodríguez D, Irazoque F, Jimenez X, Bon L, Zijlstra T, Hoekstra M, Al-Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte-Gil M, Nowakowski J, Al-Emadi S, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre-Rubio N, Sancho J, Coro M, Garcia J, Martin M, Campos J, Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Wise L, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb-Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Fatemeh E, Parks D, Karp D, Quiceno G. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals Of The Rheumatic Diseases 2021, 80: 1137-1146. PMID: 34049860, PMCID: PMC8172266, DOI: 10.1136/annrheumdis-2021-220418.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntirheumatic AgentsArthritis, RheumatoidCOVID-19FemaleHumansMaleMiddle AgedRegistriesSARS-CoV-2Severity of Illness IndexConceptsDisease-modifying antirheumatic drugsCOVID-19 severitySynthetic disease-modifying antirheumatic drugsWorse COVID-19 severityRheumatoid arthritisBaseline useCOVID-19 severity outcomeTumor necrosis factor inhibitorsInterleukin-6 inhibitorsNecrosis factor inhibitorsPotential baseline confoundersCOVID-19 outcomesPhysician registryCOVID-19IL-6iAntirheumatic drugsClinical onsetBaseline confoundersFactor inhibitorsOrdinal logistic regressionDrug classesRituximabAbataceptTNFiHospitalisation
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds